Clinics in Dermatology
Volume 26, Issue 5 , Pages 448-459 , September 2008

Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas

References 

  1. Mehlis St, Gordon KB. From laboratory to clinic: rationale for biologic therapy. In:  Menter A,  Cather J editor. Dermatologic clinics—psoriasis. Philadelphia: Saunders; 2004;p. 371–377
  2. Sterry W, Barker JN, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis. Br J Dermatol. 2004;151(suppl.):3–17
  3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407
  4. van de Kerkhof PCM. Clinical features. In:  van de Kerkhof PCM editors. Textbook of psoriasis. 2nd ed. Oxford: Blackwell; 2003;p. 3–29
  5. van de Kerkhof PCM, Franssen MEJ. Psoriasis of the scalp—diagnosis and management. Am J Clin Dermatol. 2001;2:159–165
  6. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis. 1992;49:396–400
  7. van der Vleuten CJM, van de Kerkhof PCM. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs. 2001;61:1593–1598
  8. Schoorl WJ, Baar HJ, van de Kerkhof PCM. The hair root patient in psoriasis of the scalp. Acta Derm Venereol. 1992;72:141–142
  9. Rosenberg EW, Noah PW, Skinner RB, et al. Microbial associations of 167 patients with psoriasis. Acta Derm Venereol. 1989;69(suppl.):72–75
  10. Rosenberg EW, Noah PW, Skinner RB. Microorganisms and psoriasis. J Natl Med Assoc. 1994;86:305–310
  11. van de Kerkhof PCM, de Hoop D, deKorte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197:326–334
  12. Chen SC, Yeung J, Chren MM. Scalpdex. A quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138:803–807
  13. van de Kerkhof PCM, Salonen S-H, on behalf of the EUROPSO Patient Survey Study Group. Large-scale European survey of quality of life in patients with psoriasis: second phase results on quality of life and treatment reported by 7,525 members of European psoriasis patient associations. Published by the European Federation of Psoriasis Foundations (EUROPSO), Helsinki, Finland. Available from: http://www.europso.org/ [Sept. 2006].
  14. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(suppl. 1):59–69
  15. Winterfield LS, Menter A, Gordon K, et al. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64(suppl.):87–90
  16. Winterfield LS, Menter A. Infliximab. Dermatol Ther. 2004;17:409–426
  17. Schaefer H, Redelmeier TE. In: Skin barrier—principles of percutaneous absorption. Basel: Karger; 1996;p. 153–212
  18. Callis KP, Krueger GG. Topical agents in the treatment of moderate-to-severe psoriasis. In:  Weinstein GD,  Gottlieb AB editor. Therapy of moderate-to-severe psoriasis. 2nd ed.. New York, Basel: Marcel Dekker; 2003;p. 29–51
  19. Papp K, Berth-Jones J, Kragballe K, et al. Scalp psoriasis—new treatment options are needed. In: Poster. 15th Congress of the EADV, October, 4-8. 2006;Rhodos, Greece
  20. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002;146:351–364
  21. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%–salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicentre study. Clin Ther. 1998;20:283–291
  22. Galewski E. Über Cignolin, ein Ersatzpräparat des Chrysarobins. Dermatol Wochenschr. 1916;62:113–115
  23. Haas N, Wulff-Woesten A, Sterry W, et al. Dithranol in the treatment of scalp psoriasis. J Dtsch Dermatol Ges. 2003;1:688–693
  24. Schäfer-Korting M, Gysler A. Topical glucocorticoids with improved benefit/risk ratio. In:  Korting HC,  Schäfer-Korting M editor. The benefit/risk ratio: a handbook for the rational use of potentially hazardous drugs. Boca Raton: CRC Press; 1999;p. 359–372
  25. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121:63–67
  26. Niedner R, Ziegenmeyer J. In: Dermatika—Therapeutischer Einsatz, Pharmakologie und Pharmazie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 1992;p. 76–88
  27. Roeder A, Schaller M, Schafer-Korting M, et al. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol. 2005;18:3–11
  28. Wozel G. Is the psoriasis plaque test still relevant in the age of biologicals?. Hautarzt. 2006;57:672–678
  29. van de Kerkhof PCM, Vissers WHPM. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 2003;16:69–83
  30. Pauporte M, Maibach H, Lowe N, et al. Fluocinolone acetonide topical oil or scalp psoriasis. J Dermatol Treat. 2004;15:360–364
  31. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol. 1991;24:443–447
  32. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628–632
  33. Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol. 2001;2:89–93
  34. Andreassi L, Giannetti A, Milani M Scale investigators Group. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol. 2003;148:134–138
  35. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185–192
  36. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(suppl.):39–49
  37. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48:181–183
  38. Morimoto S, Yoshikawa K, Kozuka T, et al. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol. 1986;115:421–429
  39. Fogh K, Kragballe K. New vitamin D analogs in psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:99–204
  40. van de Kerkhof PCM, Kragballe K. Recommendations for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2005;19:495–499
  41. Kragballe K. Calcipotriol: a new drug for topical psoriasis treatment. Pharmacol Toxicol. 1995;77:241–246
  42. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol. 2001;2:95–120
  43. Workshop on topical treatment options in psoriasis vulgaris. In: Meeting of the Copenhagen Psoriasis Working group. December, 12-13. 2003;Copenhagen, Denmark
  44. Thaci D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology. 2001;203:153–156
  45. Duweb GA, Abuzariba O, Rahim M, et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res. 2000;20:65–68
  46. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol. 1994;130:483–487
  47. Barnes L, Altmeyer P, Forstrom L, et al. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol. 2000;10:199–204
  48. Buckley C, Hoffmann V. Calcipotriol plus betamethasone dipropionate gel (LEO80185) is effective and safe in the treatment of scalp psoriasis (a phase II study). J Eur Acad Dermatol Venereol. 2005;19(suppl. 2):175
  49. Farber EM, Nall L. Nail psoriasis. Cutis. 1992;50:174–178
  50. van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. Dermatol Clin. 2000;18:37–46
  51. de Jong EMGJ, Seegers BAMPA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300–303
  52. Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206–212
  53. de Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25:357–362
  54. Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol. 2003;149:207–209
  55. Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82:140
  56. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68:355–358
  57. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139:655–659
  58. Zakeri M, Valikhani M, Mortazavi H, et al. Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol J Onlin. 2005;11:5
  59. deJong EM, Menke HE, van Praag MC, et al. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration–enhancing vehicle: a double-blind study. Dermatology. 1999;199:313–318
  60. Frederiksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol. 1974;110:735
  61. Schissel DJ, Elston DM. Topical 5-fluourouracil treatment for psoriatic trachyonychia. Cutis. 1998;62:27–28
  62. Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology. 2003;206:153–156
  63. Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg. 2004;8:122–125
  64. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol. 1998;25:231–233
  65. Arnold WP, Gerritsen MJ, van de Kerkhof PCM. Response of nail psoriasis to cyclosporin. Br J Dermatol. 1993;129:750–751
  66. Mahrle G, Schulze HJ, Färber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol. 1995;32:78–88
  67. Baran R. Retinoids and the nails. J Dermatol Treat. 1990;1:151–159
  68. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374
  69. Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 2006;5:339–340
  70. Rich P, Gupta A, Wang A, et al. Etanercept improves nail psoriasis. J Am Acad Dermatol. 2005;52(suppl. 3):184
  71. Sobera J, Parrish C, Elewski B. Improvement in nail psoriasis with alefacept. J Am Acad Dermatol. 2004;50(suppl. 3):145
  72. Flytstroem I, Bergbrant IM, Braared J, et al. Microorganisms in intertriginous psoriasis: no evidence of Candida. Acta Derm Venereol. 2003;83:121–123
  73. Vissers WHPM, Roelofzen J, DeJong EMGJ, et al. Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation. Eur J Dermatol. 2005;15:3–17
  74. Barardesca E, Maibach HI. Skin occlusion: treatment or drug-like device?. Skin Pharmacol. 1988;1:207–215
  75. Thaci D, Paetzold S, Kaufmann R. Treatment of intertriginous and genito-anal psoriasis. Akt Dermatol. 2003;29:505–508
  76. Lebwohl MG, Tan MH, Meador SL, et al. Limited application of fluticasone propionate ointment, 0,005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol. 2001;44:77–82
  77. Kreuter A, Sommer A, Hyun J, et al. 1% Pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol. 2006;142:1138–1143
  78. Duweb GA, Eldebani S, Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React. 2003;25:127–130
  79. Kienbaum S, Diercks K, Lehmann P, et al. Calcipotriol in the treatment of intertriginous psoriasis. Zeitschr Hautkr. 1995;70:764–766
  80. Schlehaider UK, Kowalzick L. Cream based calcipotriol for the treatment of inverse psoriasis and seborrheic dermatitis. Akt Dermatol. 1996;22:345–348
  81. Travis LB, Silverberg NB. Psoriasis in infancy. Therapy with calcipotriene ointment. Cutis. 2001;68:341–344
  82. Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 μg g−1 ointment and calcipotriol 50 μg g−1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003;148:326–333
  83. Kienbaum S, Lehmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol. 1996;135:647–650
  84. Langner A, Stapor V, Verjans H, et al. Calcitriol ointment in the treatment of facial, hairline and retroauricular chronic plaque psoriasis. J Dermatol Treat. 1996;7(suppl.):15–18
  85. Gang W, Chunying L, Tianwen G, et al. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study. Eur J Dermatol. 2005;15:176–178
  86. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111:396–398
  87. Freeman AK, Linowski GJ, Brady Ch, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48:564–568
  88. Kleyn CE, Woodcock D, Sharpe GR. The efficacy of 0,1% tacrolimus ointment compared with clobetasonebutyrate 0,05% ointment in patients with facial, flexural or genital psoriasis. Br J Dermatol. 2005;153:p33
  89. Lebwohl MG, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51:723–730
  90. Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E, et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol. 2006;5:334–336
  91. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53:713–716
  92. Wohlrab J. Calcineurin inhibitors for topical therapy in psoriasis. Hautarzt. 2006;57:685–689
  93. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51:731–738

PII: S0738-081X(07)00249-0

doi: 10.1016/j.clindermatol.2007.10.026

Clinics in Dermatology
Volume 26, Issue 5 , Pages 448-459 , September 2008

Article Tools

* Image Usage & Resolution